hacklink hack forum hacklink film izle hacklink marsbahisizmir escortsahabetpornJojobetcasibompadişahbetGorabetcasibom9018betgit casinojojobetmarsbahismatbetmatbet

Tag: Interventions

  • Holistic lifestyle interventions outshine drugs in preventing cardiometabolic diseases

    Holistic lifestyle interventions outshine drugs in preventing cardiometabolic diseases

    While lifestyle interventions show promise in tackling cardiometabolic diseases, their long-term success hinges on policy-driven environments that make healthy living accessible for all.

    Study: Lifestyle interventions for cardiometabolic health. Image Credit: Shutterstock AI

    Study: Lifestyle interventions for cardiometabolic health. Image Credit: Shutterstock AI

    A recent study published in the journal Nature Medicine reviewed the benefits of combined lifestyle interventions (CLIs) on cardiometabolic health.

    Obesity and overweight are risk factors for cardiometabolic diseases (CMDs), and their global prevalence has tripled in recent decades. Societal changes have shifted from leisure activities or labor-intensive work to more sedentary and inactive lifestyles. Concurrently, dietary patterns have shifted from plant-based diets to Western diets that are characterized by high-energy, low-fiber, and high-sugar foods. The study highlights that these trends disproportionately affect socioeconomically disadvantaged populations, where CMD prevalence can be up to five times higher than in more affluent groups.

    CLIs target multiple lifestyle behaviors and have the potential to prevent CMD in at-risk populations. However, in the long term, they are not always sustainable, and their effects attenuate in routine care. In the present study, researchers reviewed the short—and long-term benefits and cost-effectiveness of CLIs for obesity, overweight, and related CMDs in controlled studies and routine care.

    Contributions of Lifestyle Behaviors to CMD Risk

    Unhealthy diets high in saturated fat, sodium, and added sugar and low intake of fruits and vegetables are major contributors to premature mortality related to CMDs. Collectively, they account for up to 35% of cardiovascular disease (CVD)-related deaths. In addition, physical inactivity impacts CMD development and contributes an estimated 6% and 7% to CVD and type 2 diabetes (T2D) burden, respectively.

    Moreover, sedentary behavior also increases the risk of CMDs. Although other lifestyle behaviors, such as chronic stress and sleep deprivation, are associated with a greater CMD risk, their contribution to the global CMD burden is unclear. The study highlights that unhealthy behaviors often cluster, particularly in disadvantaged communities, compounding the risk of premature death. Therefore, addressing multiple lifestyle behaviors concurrently is crucial to improving cardiometabolic health.

    Effects of CLIs

    CLIs are delivered by health professionals in structured and controlled programs and commonly target sedentary, physical activity, and dietary behaviors. Evidence indicates that CLIs have consistently reduced T2D incidence by about 40% over three to six years of intervention in high-risk individuals compared to usual care in controlled settings.

    CLI effects are mainly driven by decreases in glycemic markers, body weight, blood pressure, and low-density lipoprotein cholesterol. Further, studies comparing CLIs to metformin, a glucose-lowering medicine, observed that the drug was about half as effective as CLIs. A network meta-analysis found that a CLI reduced T2D risk by 60% compared to pharmacotherapy, and this effect was partly persistent for many years post-intervention. For instance, the Finnish Diabetes Prevention Study reported a sustained 20% reduction in diabetes incidence 20 years after the intervention, highlighting the potential for long-term benefits.

    Longitudinal evaluations of CLIs beyond the active intervention period have revealed T2D risk reduction, albeit to a lesser extent, over 3–20 years of follow-up. Despite these long-term benefits, meta-analyses have not observed long-term benefits of CLIs on CVD or all-cause mortality. However, the Da Qing Diabetes Prevention Study in China demonstrated a significant reduction in all-cause and CVD mortality after 23 years of follow-up, underlining the variability in outcomes across different settings.

    CLI Implementation and Cost-Effectiveness

    Studies have translated controlled CLIs to routine care settings, given their promising effects on T2D risk. A meta-analysis of 25 translational or before-after studies found about a third to half of the effectiveness noted in the original studies, with a clinically relevant weight loss after one year, leading to improvements in CMD risk factors.

    Based on these analyses, diabetes prevention programs were implemented for high-risk individuals in Finland, the United States, Australia, and the United Kingdom. However, there is limited evidence on the effectiveness of these implementations, although the programs appear effective for people who completed them. Regarding the cost-effectiveness of CLIs, there is a paucity of evidence in routine practice. The study emphasizes the need for further economic evaluations, particularly in low- and middle-income countries where CMD prevalence is rising rapidly.

    Population-Level Approaches for Healthy Lifestyles

    Although CLIs have been effective at CMD prevention, targeting only high-risk individuals in routine care is insufficient to curb metabolic disease prevalence in the population. Therefore, measures targeting the entire population are needed. Population-based approaches have been successful in reducing smoking by 27% to 37%; this could be exemplary in informing policy decisions affecting other lifestyle behaviors.

    Urban planning policies can also play a pivotal role in reducing CMD risk. For example, designing walkable neighborhoods and increasing access to green spaces have been associated with lower rates of T2D and CVD. Similarly, implementing sugar-sweetened beverage taxes and subsidizing fruits and vegetables can positively influence dietary habits, particularly in underserved populations.

    Concluding Remarks

    While CLIs yield CMD benefits in trials and clinically relevant improvements in translational studies, their long-term effects in routine practice require further evaluation. In addition, drivers and barriers to implementing CLIs in routine practice should be evaluated. Together, CLIs can yield clinically relevant metabolic health effects, especially when reinforced by policy measures and supportive environments targeting population-level lifestyle behaviors. As such, CLIs should remain an essential component of approaches to combat the CMD epidemic.

    Source link

  • How lifestyle medicine interventions can improve well-being

    How lifestyle medicine interventions can improve well-being

    November 08, 2024

    4 min watch


    We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

    ORLANDO — Lifestyle medicine interventions can improve medical students’ well-being and reduce physician burnout, according to an expert.

    At the annual American College of Lifestyle Medicine conference, Carmen C. Lewis, PhD, MBA, vice president of institutional effectiveness at the Alabama College of Osteopathic Medicine, presented a poster on how she and her colleagues have applied lifestyle medicine in the context of medical education.

    “Our opportunity is pretty great in terms of being able to establish a connection with lifestyle medicine through it as a vehicle with our students there who are going to ultimately become future physicians,” Lewis told Healio. “The idea there is we want to introduce them to these concepts earlier in their career, and then we’d love to see them apply that with their future patients going forward.”

    The need for lifestyle medicine “is clearly there,” Lewis said.

    “There’s a high level of burnout with physicians, and an opportunity to influence well-being positively,” she added. “We’ve tried to be creative.”

    Among the specific interventions Lewis and colleagues have evaluated to influence well-being are creating “nice outdoor spaces” like a community garden where students are encouraged to grow their own plants, nutrition and cooking classes, a sand volleyball court and more.

    To evaluate the effect these interventions might have had, Lewis said they have partnered with Gallup, which administers a robust survey to see how well-being is improving among both students and staff.

    “We’ve seen our scores improve each year, and so we’re hopeful that we’re going to continue this as a longitudinal study and continue to measure it and introduce new items that we hope will continue to improve their well-being and ultimately make for an improved lifestyle,” Lewis said.

    Source link

  • Lifestyle interventions can slow or reverse some illnesses | Health

    Lifestyle interventions can slow or reverse some illnesses | Health

    HAVE YOU ever gone to the doctor and spent more time talking about how to treat your symptoms, rather than what is causing them? Have you been prescribed medications that merely mask your symptoms, or even make them worse?

    Addressing the root cause of your symptoms is at the heart of understanding your ailments, and this can be a game changer in achieving lasting health and wellness.

    According to Dr Orlando Thomas, medical doctor and functional medicine practitioner at Thomas Medical and Shockwave Centre, understanding the root cause of a disease is like unravelling a mystery. Symptoms are often manifestations of an underlying imbalance or dysfunction within the body.

    “For instance, chronic conditions like diabetes, autoimmune diseases, or digestive disorders may have multifaceted origins. Addressing the root cause involves identifying these origins – be it genetic, environmental, or lifestyle-related – and developing a personalised strategy to restore balance,” he said.

    Dr Thomas, who was the main speaker at the ‘Transforming Lives Through Healthy Living’ series of presentations held at the Portmore Seventh-day Adventist Church, said the human body is a complex system, and illness often arises from imbalances within this system.

    “These imbalances can be triggered by various factors, including poor nutrition, stress and environmental toxins. By identifying and addressing these root causes, we can alleviate symptoms that also promote long-term health and well-being,” Dr Thomas said.

    According to the World Health Organization (WHO), the world’s biggest killer is ischaemic heart disease, responsible for 13 per cent of the world’s total deaths. Since 2000, the largest increase in deaths has been caused by this disease, rising by 2.7 million to 9.1 million deaths in 2021.

    As a newly emerged cause of deaths, COVID-19 was directly responsible for 8.8 million deaths in 2021, and consequently, largely pushed down other leading causes of death by one place. Instead of being the second- and third-leading causes of death as in 2019, stroke and chronic obstructive pulmonary disease became the third and fourth in 2021, responsible for approximately 10 per cent and five per cent of total deaths, respectively.

    Lower respiratory infections remained the world’s most deadly communicable disease other than COVID-19, ranked as the fifth-leading cause of death. However, the number of deaths has gone down substantially: in 2021 it claimed 2.5 million lives, 370,000 fewer than in 2000.

    Deaths from other non-communicable diseases were also on the rise. Trachea, bronchus and lung cancers deaths have risen from 1.2 million in 2000 to 1.9 million in 2021 and are now ranked sixth among leading causes of death.

    According to Dr Thomas, in conventional medicine, medical practitioners tend to treat these diseases individually, but most people that have one of these illnesses also have three or more that are referred to as comorbidities.

    “They all go together. Most diabetics have hypertension and poor circulation, and may be at the risk of getting a stroke or a heart attack. The question is, why do many of these diseases go together? Because the root causes are the same, and as such, reversing these diseases also takes the same or similar strategies,” he said.

    Addressing the root causes of illnesses, he said, represents a paradigm shift in our approach to health and wellness. By focusing on the underlying imbalances that give rise to disease, we can move beyond symptom management to truly promote health and vitality.

    Many people suffer from different factors, including chronic stress, poor diet, and the lack of sleep. By addressing these underlying issues, he said, we can enhance our body’s natural ability to fight off illness. “As we continue to face new health challenges, this holistic approach will be critical in supporting our collective well-being,” Dr Thomas said.

    COMMON THINGS TO LIVE LONGER:

    • Good nutrition: What you eat has a direct impact on the cells in your body, which in turn has an impact on longevity. A healthy diet provides cells with vital sources of energy and keeps them stable and working as they should. Healthy foods support your immune cells, which defend against infections and other health threats, protect other cells from damage, and help the body repair or replace damaged cells.

    • Role of exercise: Many studies show that physical activity contributes to greater longevity, due to the many positive effects it has on the body. These effects include stronger heart and lung function, improved health of blood vessels, stronger muscles, better balance, and a healthier weight.

    OTHER LIFESTYLE CHOICES THAT CONTRIBUTE TO LONGEVITY:

    In addition to healthy eating and being more active, the following lifestyle choices can have an enormous impact on longevity and quality of life:

    • Do not smoke: Smoking has been proven to shorten lifespan. Smoking damages lung function, hearth, skin and oral health, and it increases the risk of cancer.

    • Limit alcohol: Excessive alcohol use increases your risk of liver damage, cancer, and serious accidents. It can impair your immune system and result in depression. Drinking alcohol in moderation means one drink or less per day for women, and two drinks or less per day for men.

    • Get enough sleep: Getting quality sleep is vital to good health and well-being throughout your life and may even extend it. Over time, inadequate sleep can raise your risk for chronic health problems, affecting your heart, brain, lungs, immune system, and more.

    • Hydrate: Those who stay well hydrated appear to be healthier, develop fewer chronic conditions like heart and lung disease, and live longer than those who do not.

    • Socialise: More frequent social activity was associated with significantly longer survival. In fact, the greater the frequency of socialisation, the greater the likelihood of living longer.

    • Think positive: You may be surprised that your outlook on life can contribute to longevity. Two recent studies found that optimism is linked to a longer lifespan in women from diverse racial and ethnic groups, and to better emotional health in older men.

    keisha.hill@gleanerjm.com

    SOURCE: World Health Organization

    Source link

  • Liraglutide with Lifestyle Interventions Decreased BMI for Children 6 to 11

    Liraglutide with Lifestyle Interventions Decreased BMI for Children 6 to 11

    An intervention combining liraglutide with a lifestyle intervention was more effective for children with obesity aged 6 to 11 years old compared with the study placebo. With most literature surrounding weight-loss medications focusing on adults or children 12 years or older, recent findings that liraglutide can help children with obesity aged 6 to 11 speaks further to the overall efficacy of weight-loss medications for the management of obesity.

    “The glucagon-like peptide-1 (GLP-1) analogues liraglutide and semaglutide are approved by the Food and Drug Administration (FDA) and the European Medicines Agency for long-term weight management in adolescents 12 years of age or older with obesity, as adjunct treatments to lifestyle interventions,” wrote authors of a study published in the New England Journal of Medicine.1

    Put It Into Practice

    Incorporate these strategies into your pharmacy practice to improve patient outcomes.

    • Promote adherence and lifestyle support so that children prescribed liraglutide for obesity can properly balance their interventions.
    • Monitor adverse effects and drug reactions so that children and their families can be certain that liraglutide is right for them.
    • Offer medication counseling for families who may be new to weight-loss drugs like liraglutide and other GLP-1s.

    GLP-1s have taken the pharmaceutical industry by storm both because of their efficacy in treating weight-loss as well as other comorbidities like cardiovascular disease (CVD) and diabetes. Indeed, according to the American Society of Health-System Pharmacists 2024 report, weight-loss drugs have overtaken the prescription drug market and were key drivers of the 13.5% increase in drug expenditures in 2023.2

    However, when it comes to nonmonogenic, nonsyndromic weight-loss drugs, there has not yet been a GLP-1 approved for use amongst children with obesity under 12 years old.1 Instead, lifestyle interventions, including a healthy amount of nutritious food and physical activity, have been the primary modes of managing obesity for children under 12. But as GLP-1s become more popular and effective for weight-loss—and lifestyle interventions continue to show modest results—researchers are now exploring the use of GLP-1s for younger age groups.

    For children 6 to 11, liraglutide at a dose of 3.0 mg plus lifestyle interventions resulted in a greater reduction in BMI than placebo plus lifestyle interventions. | image credit: luchschenF / stock.adobe.com

    “In this phase 3a trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we randomly assigned children (6 to <12 years of age) with obesity, in a 2:1 ratio, to receive either once-daily subcutaneous liraglutide at a dose of 3.0 mg (or the maximum tolerated dose) or placebo, plus lifestyle interventions. The primary end point was the percentage change in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters),” wrote authors of the study.1

    READ MORE: A Deeper Understanding of GLP-1 Mechanism of Action Will Open Doors for Future Uses

    A total of 82 participants were included in the randomized trial, with 56 receiving liraglutide and 26 placed into a placebo group. Participants were monitored throughout a 56-week period, with a 5% reduction in BMI as the marker for liraglutide to be considered effective.

    For individuals in the liraglutide group, the mean percentage change in BMI was a 5.8% decrease, while individuals in the placebo group experienced a mean BMI increase of 1.6%. Furthermore, 46% of the liraglutide group saw a BMI reduction of at least 5%, with only 9% of the placebo group achieving a 5% BMI reduction.

    “At week 56, the difference between the liraglutide and placebo groups was −7.4 percentage points for the change from baseline in BMI and −8.4 percentage points for the change from baseline in body weight,” wrote the authors.1 “This phase 3a trial adds to the base of evidence for the management of pediatric obesity. The superiority of liraglutide over placebo was shown with respect to the primary end point.”

    Researchers mentioned that results of this phase 3a clinical trial will advise future studies regarding GLP-1 use among children under 12. A previous study analyzing BMI in youth populations found that, on average, the most extreme changes in weight occur between the years of 2 and 6. While the use of GLP-1s are gradually being considered for younger populations, it wouldn’t be unlikely for researchers to begin exploring the use of weight-loss drugs for children under the age of 6.

    In line with other studies regarding GLP-1 use for treating CVD and diabetes, researchers also found that liraglutide helped improve diastolic blood pressure and glycated hemoglobin level.1 Indeed, previous trials have highlighted the efficacy of semaglutide to treat CVD and patients with diabetes experiencing chronic kidney disease.3

    However, as researchers explore the use of GLP-1s for treating conditions aside from obesity, they too will continue to study GLP-1s among younger populations that are overweight. “I definitely think this is a realization that diet and exercise is not going to do it for a number of teens who are struggling with this—maybe the majority,” Stephanie Byrne, MD, a pediatrician in Los Angeles, told STAT News.4

    With adult and childhood obesity persisting as a major health concern within the US, researchers and patients alike are looking toward medications to expedite weight-loss across the country. The results of this study should serve as yet another page in the story of GLP-1s and their rise to popularity among older adults, adolescents, and now children.

    “This trial showed that among children 6 to younger than 12 years of age with obesity, liraglutide at a dose of 3.0 mg plus lifestyle interventions resulted in a greater reduction in BMI than placebo plus lifestyle interventions,” concluded the authors.1

    READ MORE: Teva Pharmaceuticals Launches Liraglutide Injection 1.8 mg, First Generic GLP-1 in the US

    Pharmacy practice is always changing. Stay ahead of the curve: Sign up for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.

    References
    1. Fox CK, Barrientos-Pérez M, Bomberg EM. Liraglutide for children 6 to <12 years of age with obesity: A randomized trial. New England Journal of Medicine. Published online September 10, 2024. doi.org/10.1056/nejmoa2407379
    2. Enormous demand for weight-loss drugs drives up total U.S. prescription spending. PR Newswire. April 24, 2024. Accessed May 2, 2024. https://www.prnewswire.com/news-releases/enormous-demand-for-weight-loss-drugs-drives-up-total-us-prescription-spending-302125178.html
    3. Rubin R. Could GLP-1 receptor agonists like semaglutide treat addiction, Alzheimer disease, and other conditions? JAMA. Published online April 19, 2024. doi:10.1001/jama.2024.1017
    4. Aleccia J. Pediatricians recommend weight-loss drugs and surgery for children with obesity. STAT News. January 9, 2023. Accessed September 16, 2024. https://www.statnews.com/2023/01/09/pediatricians-children-obesity/

    Source link

  • Liraglutide with Lifestyle Interventions Decreased BMI for Children 6 to 11

    Liraglutide with Lifestyle Interventions Decreased BMI for Children 6 to 11

    An intervention combining liraglutide with a lifestyle intervention was more effective for children with obesity aged 6 to 11 years old compared with the study placebo. With most literature surrounding weight-loss medications focusing on adults or children 12 years or older, recent findings that liraglutide can help children with obesity aged 6 to 11 speaks further to the overall efficacy of weight-loss medications for the management of obesity.

    “The glucagon-like peptide-1 (GLP-1) analogues liraglutide and semaglutide are approved by the Food and Drug Administration (FDA) and the European Medicines Agency for long-term weight management in adolescents 12 years of age or older with obesity, as adjunct treatments to lifestyle interventions,” wrote authors of a study published in the New England Journal of Medicine.1

    Put It Into Practice

    Incorporate these strategies into your pharmacy practice to improve patient outcomes.

    • Promote adherence and lifestyle support so that children prescribed liraglutide for obesity can properly balance their interventions.
    • Monitor adverse effects and drug reactions so that children and their families can be certain that liraglutide is right for them.
    • Offer medication counseling for families who may be new to weight-loss drugs like liraglutide and other GLP-1s.

    GLP-1s have taken the pharmaceutical industry by storm both because of their efficacy in treating weight-loss as well as other comorbidities like cardiovascular disease (CVD) and diabetes. Indeed, according to the American Society of Health-System Pharmacists 2024 report, weight-loss drugs have overtaken the prescription drug market and were key drivers of the 13.5% increase in drug expenditures in 2023.2

    However, when it comes to nonmonogenic, nonsyndromic weight-loss drugs, there has not yet been a GLP-1 approved for use amongst children with obesity under 12 years old.1 Instead, lifestyle interventions, including a healthy amount of nutritious food and physical activity, have been the primary modes of managing obesity for children under 12. But as GLP-1s become more popular and effective for weight-loss—and lifestyle interventions continue to show modest results—researchers are now exploring the use of GLP-1s for younger age groups.

    For children 6 to 11, liraglutide at a dose of 3.0 mg plus lifestyle interventions resulted in a greater reduction in BMI than placebo plus lifestyle interventions. | image credit: luchschenF / stock.adobe.com

    “In this phase 3a trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we randomly assigned children (6 to <12 years of age) with obesity, in a 2:1 ratio, to receive either once-daily subcutaneous liraglutide at a dose of 3.0 mg (or the maximum tolerated dose) or placebo, plus lifestyle interventions. The primary end point was the percentage change in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters),” wrote authors of the study.1

    READ MORE: A Deeper Understanding of GLP-1 Mechanism of Action Will Open Doors for Future Uses

    A total of 82 participants were included in the randomized trial, with 56 receiving liraglutide and 26 placed into a placebo group. Participants were monitored throughout a 56-week period, with a 5% reduction in BMI as the marker for liraglutide to be considered effective.

    For individuals in the liraglutide group, the mean percentage change in BMI was a 5.8% decrease, while individuals in the placebo group experienced a mean BMI increase of 1.6%. Furthermore, 46% of the liraglutide group saw a BMI reduction of at least 5%, with only 9% of the placebo group achieving a 5% BMI reduction.

    “At week 56, the difference between the liraglutide and placebo groups was −7.4 percentage points for the change from baseline in BMI and −8.4 percentage points for the change from baseline in body weight,” wrote the authors.1 “This phase 3a trial adds to the base of evidence for the management of pediatric obesity. The superiority of liraglutide over placebo was shown with respect to the primary end point.”

    Researchers mentioned that results of this phase 3a clinical trial will advise future studies regarding GLP-1 use among children under 12. A previous study analyzing BMI in youth populations found that, on average, the most extreme changes in weight occur between the years of 2 and 6. While the use of GLP-1s are gradually being considered for younger populations, it wouldn’t be unlikely for researchers to begin exploring the use of weight-loss drugs for children under the age of 6.

    In line with other studies regarding GLP-1 use for treating CVD and diabetes, researchers also found that liraglutide helped improve diastolic blood pressure and glycated hemoglobin level.1 Indeed, previous trials have highlighted the efficacy of semaglutide to treat CVD and patients with diabetes experiencing chronic kidney disease.3

    However, as researchers explore the use of GLP-1s for treating conditions aside from obesity, they too will continue to study GLP-1s among younger populations that are overweight. “I definitely think this is a realization that diet and exercise is not going to do it for a number of teens who are struggling with this—maybe the majority,” Stephanie Byrne, MD, a pediatrician in Los Angeles, told STAT News.4

    With adult and childhood obesity persisting as a major health concern within the US, researchers and patients alike are looking toward medications to expedite weight-loss across the country. The results of this study should serve as yet another page in the story of GLP-1s and their rise to popularity among older adults, adolescents, and now children.

    “This trial showed that among children 6 to younger than 12 years of age with obesity, liraglutide at a dose of 3.0 mg plus lifestyle interventions resulted in a greater reduction in BMI than placebo plus lifestyle interventions,” concluded the authors.1

    READ MORE: Teva Pharmaceuticals Launches Liraglutide Injection 1.8 mg, First Generic GLP-1 in the US

    Pharmacy practice is always changing. Stay ahead of the curve: Sign up for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.

    References
    1. Fox CK, Barrientos-Pérez M, Bomberg EM. Liraglutide for children 6 to <12 years of age with obesity: A randomized trial. New England Journal of Medicine. Published online September 10, 2024. doi.org/10.1056/nejmoa2407379
    2. Enormous demand for weight-loss drugs drives up total U.S. prescription spending. PR Newswire. April 24, 2024. Accessed May 2, 2024. https://www.prnewswire.com/news-releases/enormous-demand-for-weight-loss-drugs-drives-up-total-us-prescription-spending-302125178.html
    3. Rubin R. Could GLP-1 receptor agonists like semaglutide treat addiction, Alzheimer disease, and other conditions? JAMA. Published online April 19, 2024. doi:10.1001/jama.2024.1017
    4. Aleccia J. Pediatricians recommend weight-loss drugs and surgery for children with obesity. STAT News. January 9, 2023. Accessed September 16, 2024. https://www.statnews.com/2023/01/09/pediatricians-children-obesity/

    Source link